Amniotic membrane preparations and purified compositions and anti-inflammation methods

• US 20070231401A1
• Filed: 09/27/2006
• Published: 10/04/2007
• Est. Priority Date: 09/27/2005
• Status: Active Grant

• Current Assignee: Biotissue Holdings Incorporated
• Original Assignee: Bio-Tissue, Inc. (Tissuetech, Inc.)
• Inventors: Li, Wei, He, Hua, Tseng, Scheffer
• Granted Patent: US 8,182,841 B2
• Time in Patent Office: Days
• US Class Current: 424/528
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/74 Biological properties of particular ingredients
• CPC Class Codes: A61K 31/738 Cross-linked polysaccharides
• CPC Class Codes: A61K 35/48 Reproductive organs
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61K 8/982 Reproductive organs; Embryos, Eggs
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61L 15/40 containing ingredients of undetermined constitution or reaction products thereof , e.g. plant or animal extracts
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: C07K 14/4702 : Regulators; Modulating activity
• CPC Class Codes: C07K 14/4718 : Cytokine-induced proteins
• CPC Class Codes: C07K 14/78 : Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 14/8114 : Kunitz type inhibitors

Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Claims

1. A method for reducing or preventing inflammation in a subject comprising the step of providing an effective amount of an inflammation inhibition composition to a subject in need of inflammation inhibition or prevention;

wherein the inflammation inhibition composition comprises at least one component prepared from a human amniotic material selected from a human amniotic membrane, a human amniotic jelly, a human amniotic stroma, or a combination thereof extracted from an amniotic membrane.

2. The method of claim 1, wherein at least one component was extracted from the human amniotic material.

3. The method of claim 2, wherein the human amniotic material is the human amniotic membrane.

4. The method of claim 1, wherein the composition comprises:

Cross-linked high molecular weight hyaluronan (HA);

Tumor necrosis factor-stimulated gene 6 (TSG-6);

Pentraxin (PTX-3); and

Thrombospondin (TSP-1).

5. The method of claim 2, wherein the extraction procedure comprises:

Obtaining a frozen or previously-frozen human placenta;

Thawing the placenta and isolating the human amniotic material from the thawed placenta;

Homogenizing the human amniotic material in a suitable buffer;

Optionally lyophilizing the homogenate to a powder; and

Admixing the homogenate or the powder with a pharmaceutically acceptable carrier for a non-solid dosage form or an extended release solid dosage form.

6. The method of claim 5, wherein the preparation procedure substitutes the step of lyophilizing the homogenate with the step of:

Centrifuging the homogenate, isolating the supernatant from the centrifuged homogenate, and optionally lyophilizing the supernatant to a powder.

7. The method of claim 1, wherein the human has arthritis.

8. The method of claim 1, wherein the human has inflammation in at least one eye.

9. The method of claim 1, wherein the inflammation inhibition composition is provided as a non-solid dosage form or an extended release solid dosage form.

10. The method of claim 1, wherein the inflammation inhibition composition has at least two of the following properties:

induces apoptosis of macrophages at the site of inflammation;

increases the ratio of prostaglandin D2 to prostaglandin E1 at the site of inflammation;

suppresses TGF-β

1 activity at the site of inflammation;

or

inhibits interferon-gamma signal transduction at the site of inflammation.